Redwood Pharma
Redwood Pharma develops ophthalmic drugs in areas where medical need is especially great.
This is an approach exemplified by our very first project. RP101 treats chronic dry eyes in post-menopausal women. Something that is possible thanks to our drug delivery platform IntelliGel, which controls the release of active substances. The platform also supports improved dosages of other established drugs.
Dry eye disease (DED) offers enormous potential. A total of some 344 million people are affected, equivalent to a global market of USD 3.1 billion. And the market is expected to grow, not least due to the lack of effective treatments.
This is something we want to change. Our strategy is to sign licence agreements with drug companies that will manufacture and market products on the global market.
Redwood Pharma AB (publ.) is listed on the Nasdaq First North Growth Market (ticker: REDW, ISIN: SE008294789).
in Feb. 12 2012 with HQ in Stockholm, Sweden
Development of new opthalmic medicines
Nasdaq First North Growth Market (REDW)
Topical therapy for Dry Eye Disease
of external expertise in production, quality and regulatory organizations
IntelliGel hydrogel drug delivery platform
Board of Directors
Björn Larsson
Chairman of the Board since 2022
Born: 1965.
Education: MSc in Engineering from Chalmers University of Technology, Göteborg, Sweden.
Other assignments: Chairman of the Board of Alzinova AB (publ) and Vice-Chairman of IML in Sweden.
Shareholding: 0 shares (0%)
Independence in relation to the company and its management: Yes
Independence in relation to major shareholders: Yes
Ingrid Atteryd Heiman
Board member since 2016
Born: 1958.
Education: Master of Business Administration from Lund University, MBA in International Business from Uppsala University and the Board Academy’s major chair training.
Other assignments: Chairman of the Board Doxa AB, Board member Amniotics AB, Board member CarpoNovum AB, Board member Pharmiva AB and Board member of the Parkinson Research Foundation.
Shareholding: 5,550 shares (0,03%).
Independence in relation to the company and its management: Yes
Independence in relation to major shareholders: Yes
Göran Eckerwall
Board member since 2021
Born: 1956.
Education: Medical Doctor, MD, PhD, University of Lund and Diploma of Pharmaceutical Medicine, Karolinska Institute.
Other assignments: Independent Consultant as Medical Adviser.
Shareholding: 0 shares (0%).
Independence in relation to the company and its management: Yes
Independence in relation to major shareholders: Yes
Martin Vidaeus
Board member and CEO since 2012
Born: 1966.
Education: MBA from New York University, USA, and Bachelor of Science in Chemical Engineering from University of Maryland, College Park, USA.
Other assignments:
Shareholding: 1,196,082 shares (5,77%).
Independence in relation to the company and its management: No
Independence in relation to major shareholders: Yes
Management
Martin Vidaeus
Board member and CEO since 2012
Born: 1966.
Education: MBA from New York University, USA, and Bachelor of Science in Chemical Engineering from University of Maryland, College Park, USA.
Other assignments:
Shareholding: 1,196,082 shares (5,77%).
Independence in relation to the company and its management: No
Independence in relation to major shareholders: Yes
Hans Ageland
Chief Operating Officer since 2012
Born: 1961.
Education: Master of Science in Biochemistry from KTH.
Other assignments: Deputy board member Ateljé Grön AB and deputy board member Daniel & Sebastian Byggentreprenad AB.
Shareholding: 405,109 shares (1,95%).
Independence in relation to the company and its management: NoIndependence in relation to major shareholders: Yes
Ulf Björklund
Chief Medical Officer since 2016
Consultant as Chief Medical Officer since 2016.
Born: 1956.
Education: Pharmacist at Uppsala University.
Other assignments: CEO and board member UB-consulting AB, Chairman of the Board Lipum AB, boardmember Tikomed AB, boardmember MedicalNatumin AB, Chief Operating Officer Aptahem AB and Chief Scientific Officer Synartro AB.
Shareholding: 18,183 shares (0,17%)
Independence in relation to the company and its management: No
Independence in relation to major shareholders: Yes
Peter Rooslien
Chief Financial Officer since 2016
Providing consulting services as CFO since in 2016.
Born: 1956.
Education: Master of Business Administration from Stockholm University.
Other assignments: Chairman of the Board RochS Sifferkontoret AB and board member in Rooslien Ekonomikonsult AB.
Innehav: Peter Rooslien saknar innehav i Bolaget.
Independence in relation to the company and its management: No
Independence in relation to major shareholders: Yes